van den Bent, M. J., Smits, M., Kros, J. M. & Chang, S. M. Diffuse infiltrating oligodendroglioma and astrocytoma. J. Clin. Oncol. 35, 2394–2401 (2017).

Article  PubMed  Google Scholar 

Parsons, D. W. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807–1812 (2008).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765–773 (2009).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Horbinski, C., Kofler, J., Kelly, L. M., Murdoch, G. H. & Nikiforova, M. N. Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. J. Neuropathol. Exp. Neurol. 68, 1319–1325 (2009).

Article  CAS  PubMed  Google Scholar 

Capper, D., Zentgraf, H., Balss, J., Hartmann, C. & von Deimling, A. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol. 118, 599–601 (2009).

Article  CAS  PubMed  Google Scholar 

Pusch, S. et al. Glioma IDH1 mutation patterns off the beaten track. Neuropathol. Appl. Neurobiol. 37, 428–430 (2011).

Article  CAS  PubMed  Google Scholar 

Ward, P. S. et al. Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production. Oncogene 31, 2491–2498 (2012).

Article  CAS  PubMed  Google Scholar 

Gupta, R. et al. Expanding the spectrum of IDH1 mutations in gliomas. Mod. Pathol. 26, 619–625 (2013).

Article  CAS  PubMed  Google Scholar 

Ganz, J. et al. Rates and patterns of clonal oncogenic mutations in the normal human brain. Cancer Discov. 12, 172–185 (2022).

Article  CAS  PubMed  Google Scholar 

Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 23, 1231–1251 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rudà, R., Bello, L., Duffau, H. & Soffietti, R. Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments. Neuro Oncol. 14, 55–64 (2012).

Article  Google Scholar 

Weller, M. et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat. Rev. Clin. Oncol. 18, 170–186 (2021).

Article  PubMed  Google Scholar 

Miller, J. J. et al. Isocitrate dehydrogenase (IDH) mutant gliomas: a Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. Neuro Oncol. 25, 4–25 (2023).

Article  CAS  PubMed  Google Scholar 

Baumert, B. G. et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 17, 1521–1532 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Buckner, J. C. et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N. Engl. J. Med. 374, 1344–1355 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Douw, L. et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. 8, 810–818 (2009).

Article  PubMed  Google Scholar 

Johnson, B. E. et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343, 189–193 (2014).

Article  CAS  PubMed  Google Scholar 

DiNardo, C. D. et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N. Engl. J. Med. 378, 2386–2398 (2018).

Article  CAS  PubMed  Google Scholar 

Abou-Alfa, G. K. et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 21, 796–807 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tap, W. D. et al. Phase I study of the mutant IDH1 inhibitor ivosidenib: safety and clinical activity in patients with advanced chondrosarcoma. J. Clin. Oncol. 38, 1693–1701 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dang, L. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739–744 (2009).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Figueroa, M. E. et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18, 553–567 (2010).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu, W. et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 19, 17–30 (2010).

Article  Google Scholar 

Chowdhury, R. et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep. 12, 463–469 (2011).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Koivunen, P. et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 483, 484–488 (2012).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lu, C. et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483, 474–478 (2012).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Noushmehr, H. et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17, 510–522 (2010).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lai, A. et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J. Clin. Oncol. 29, 4482–4490 (2011).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carrillo, J. A. et al. Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. Am. J. Neuroradiol. 33, 1349–1355 (2012).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stockhammer, F. et al. IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom. Seizure 21, 194–197 (2012).

Article  PubMed  Google Scholar 

Chen, R. et al. Hominoid-specific enzyme GLUD2 promotes growth of IDH1R132H glioma. Proc. Natl Acad. Sci. USA 111, 14217–14222 (2014).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Waitkus, M. S. et al. Adaptive evolution of the GDH2 allosteric domain promotes gliomagenesis by resolving IDH1(R132H)-induced metabolic liabilities. Cancer Res. 78, 36–50 (2018).

Article  CAS  PubMed  Google Scholar 

Watanabe, T., Nobusawa, S., Kleihues, P. & Ohgaki, H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am. J. Pathol. 174, 1149–1153 (2009).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wolter, M. et al. Oligodendroglial tumors frequently demonstrate hypermethylation of the CDKN2A (MTS1, p16INK4a), p14ARF, and CDKN2B (MTS2, p15INK4b) tumor suppressor genes. J. Neuropathol. Exp. Neurol. 60, 1170–1180 (2001).

Article  CAS  PubMed  Google Scholar 

Alonso, M. E. et al. Aberrant promoter methylation of multiple genes in oligodendrogliomas and ependymomas. Cancer Genet. Cytogenet. 144, 134–142 (2003).

Article  CAS  PubMed  Google Scholar 

Kuo, L. T. et al. Genetic and epigenetic alterations in primary-progressive paired oligodendroglial tumors. PLoS ONE 8, e67139 (2013).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Unruh, D. et al. Methylation and transcription patterns are distinct in IDH-mutant gliomas compared to other IDH-mutant cancers. Sci. Rep. 9, 8946 (2019).